Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumomab + ICE in Relapsed/Refractory DLBCL
NCT02412267Phase 2Completed
- Sponsor
- National Cancer Centre Singapore
- Start
- Apr 2011
- Primary completion
- Dec 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ofatumumab in diffuse large B-cell lymphoma (DLBCL), sponsored by National Cancer Centre Singapore. Started Apr 2011; status: completed.
02
Drugs
ofatumumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02412267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02412267.